Market Reaction to Eli Lilly's Announcement

Novo Nordisk experienced a significant 8% drop in share prices this Tuesday, a direct response to the recent announcement by Eli Lilly and Co. regarding their successful late-stage trial of the oral weight loss drug, orforglipron.

Impact on Healthcare Stocks

The positive trial results have not only affected Novo Nordisk but also sent ripples through the healthcare sector, with several stocks witnessing a downturn following the European market's opening.

Stock Performance Details

By 11:09 am CET, Novo Nordisk's shares had decreased by 7.43%, trading at 389.30 Danish Krone. Conversely, Eli Lilly saw a modest premarket gain of 0.62% in New York, reaching $823.12.